DK2200616T3 - Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi - Google Patents

Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi

Info

Publication number
DK2200616T3
DK2200616T3 DK08794174.6T DK08794174T DK2200616T3 DK 2200616 T3 DK2200616 T3 DK 2200616T3 DK 08794174 T DK08794174 T DK 08794174T DK 2200616 T3 DK2200616 T3 DK 2200616T3
Authority
DK
Denmark
Prior art keywords
mipo
huntington
inhibitors
disease
treatment
Prior art date
Application number
DK08794174.6T
Other languages
Danish (da)
English (en)
Inventor
Haakan Eriksson
Werner Poewe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK2200616T3 publication Critical patent/DK2200616T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK08794174.6T 2007-08-23 2008-08-22 Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi DK2200616T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95752307P 2007-08-23 2007-08-23
US95752507P 2007-08-23 2007-08-23
PCT/SE2008/050950 WO2009025618A1 (en) 2007-08-23 2008-08-22 Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Publications (1)

Publication Number Publication Date
DK2200616T3 true DK2200616T3 (da) 2013-03-04

Family

ID=40378392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08794174.6T DK2200616T3 (da) 2007-08-23 2008-08-22 Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi

Country Status (25)

Country Link
US (6) US20090054468A1 (enExample)
EP (1) EP2200616B1 (enExample)
JP (2) JP5247804B2 (enExample)
KR (1) KR101588464B1 (enExample)
CN (4) CN105687199A (enExample)
AU (1) AU2008289653B2 (enExample)
BR (1) BRPI0815681A2 (enExample)
CA (1) CA2698205C (enExample)
CY (1) CY1113714T1 (enExample)
DK (1) DK2200616T3 (enExample)
EA (1) EA017510B1 (enExample)
ES (1) ES2399846T3 (enExample)
HR (1) HRP20130139T1 (enExample)
IL (2) IL203738A (enExample)
ME (1) ME01510B (enExample)
MX (1) MX2010001983A (enExample)
MY (1) MY155633A (enExample)
NZ (1) NZ584135A (enExample)
PH (1) PH12014501180A1 (enExample)
PL (1) PL2200616T3 (enExample)
PT (1) PT2200616E (enExample)
RS (1) RS52665B (enExample)
SI (1) SI2200616T1 (enExample)
WO (1) WO2009025618A1 (enExample)
ZA (1) ZA201000848B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
BR112014011254A2 (pt) 2011-11-11 2017-05-16 Pfizer 2-tiopirimidinonas
ES2587954T3 (es) * 2012-03-29 2016-10-27 Basf Se Compuestos de hetero-bicíclicos N-sustituidos y derivados para combatir plagas animales II
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
AU2016257179A1 (en) 2015-05-05 2017-11-02 Pfizer Inc. 2-thiopyrimidinones
BR112019027717A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
KR102705858B1 (ko) * 2017-07-17 2024-09-10 아스트라제네카 아베 의약에서의 사용을 위한 mpo 억제제
EP4041735A4 (en) * 2019-10-10 2023-11-22 Biohaven Therapeutics Ltd. MYELOPEROXIDASE INHIBITOR PRODRUGS
AU2021230370A1 (en) * 2020-03-05 2022-10-20 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
CN115551511A (zh) * 2020-05-06 2022-12-30 拜尔哈文制药股份有限公司 用于制备维迪泊司他的方法
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用
EP4573096A1 (en) 2022-08-18 2025-06-25 Astrazeneca AB Inhibitors of myeloperoxidase
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation
WO2024120457A1 (zh) * 2022-12-09 2024-06-13 深圳信立泰药业股份有限公司 一种吡咯并[3,2-d]嘧啶-4-酮类衍生物及其制备方法和医药用途
WO2024163892A1 (en) * 2023-02-02 2024-08-08 University Of Virginia Patent Foundation Myeloperoxidase (mpo) inhibition as a treatment target for delayed cerebral injury (dci) in aneurysmal subarachnoid hemorrhage (sah)
WO2025172474A1 (en) 2024-02-15 2025-08-21 Astrazeneca Ab Inhibitors of myeloperoxidase
WO2025190901A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Use of myeloperoxidase (mpo) inhibitors for promoting cd8+ t cell responses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
MXPA04007299A (es) * 2002-01-28 2004-10-29 Kyowa Hakko Kogyo Kk Metodos de tratamiento de pacientes que sufren de trastornos de movimiento.
AR039385A1 (es) * 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
SE0302756D0 (sv) * 2003-10-17 2003-10-17 Astrazeneca Ab Novel Compounds
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
UY30267A1 (es) * 2006-04-13 2007-11-30 Astrazeneca Ab Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
US20090124640A1 (en) * 2006-06-05 2009-05-14 Astrazeneca Ab Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor
AR066936A1 (es) * 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938

Also Published As

Publication number Publication date
CN101873857A (zh) 2010-10-27
CN113633641A (zh) 2021-11-12
CN105687199A (zh) 2016-06-22
US20200405724A1 (en) 2020-12-31
PH12014501180A1 (en) 2015-08-24
JP2010536849A (ja) 2010-12-02
EP2200616A1 (en) 2010-06-30
US20130059870A1 (en) 2013-03-07
IL203738A (en) 2015-08-31
EA017510B1 (ru) 2013-01-30
ME01510B (me) 2014-04-20
HK1145141A1 (en) 2011-04-08
EP2200616B1 (en) 2012-12-26
US20110207755A1 (en) 2011-08-25
ZA201000848B (en) 2012-07-25
EA201000202A1 (ru) 2010-10-29
RS52665B (sr) 2013-06-28
CY1113714T1 (el) 2016-06-22
AU2008289653B2 (en) 2012-06-28
JP2013151547A (ja) 2013-08-08
US20190099423A1 (en) 2019-04-04
PL2200616T3 (pl) 2013-04-30
MX2010001983A (es) 2010-03-10
WO2009025618A1 (en) 2009-02-26
AU2008289653A1 (en) 2009-02-26
US20090054468A1 (en) 2009-02-26
CA2698205A1 (en) 2009-02-26
MY155633A (en) 2015-11-13
CN103638029A (zh) 2014-03-19
EP2200616A4 (en) 2010-08-25
PT2200616E (pt) 2013-02-27
BRPI0815681A2 (pt) 2015-02-18
HRP20130139T1 (hr) 2013-03-31
NZ584135A (en) 2012-04-27
KR20100055434A (ko) 2010-05-26
ES2399846T3 (es) 2013-04-03
CA2698205C (en) 2016-06-21
IL240130A0 (en) 2015-09-24
US20140221400A1 (en) 2014-08-07
SI2200616T1 (sl) 2013-03-29
JP5247804B2 (ja) 2013-07-24
KR101588464B1 (ko) 2016-01-25
US10772890B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
DK2200616T3 (da) Mipo-hæmmere til behandling huntingtons sygdom og multipel system atrofi
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1981526A4 (en) ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS
FI20060294A0 (fi) Kalibrointimenetelmä ja -laitteisto äänentoistojärjestelmässä
SI3888584T1 (sl) Sistemi za zdravljenje zobnih ali paradontalnih težav
IL243262B (en) Systems and methods for ex vivo organ care
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
EP2147437A4 (en) SEEDING REPLICATION
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
EP2213846A4 (en) METHOD FOR REMOVING A SHAFT RING AND CONNECTING A SHOVEL RING
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI0907064A2 (pt) "métodos e sistemas"
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
BRPI0814330A2 (pt) métodos e kits cirúrgicos
DK2026819T3 (da) Forebyggelse og/eller behandling af Alzheimers sygdom
EP2236150A4 (en) METHOD FOR INCREASING THE THERAPEUTIC EFFECTIVENESS OF CURCUMINOIDS AND ANALOGUE
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
BRPI0818741A2 (pt) equipamento e método de avaliação da presença de microorganismos no sangue
HRP20160569T1 (hr) Boropeptidni inhibitori enteropeptidaze i njihove uporabe u liječenju pretilosti, pretjerane tjelesne težine i/ili bolesti povezane s abnormalnim metabolizmom masti
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
HUE032901T2 (hu) Készítmények és eljárások csontnövekedés elõidézésére és csontvesztés gátlására
DK1999403T3 (da) Multikoblingssystem og fremgangsmåde relateret dertil
DK1974592T3 (da) Kølesystem og -fremgangsmåde
SE0700997L (sv) Fastsättningsapparat och -system
EP2210621A4 (en) COMPOSITION FOR TREATING JOINT DISEASE